SEYLTX
Ifenprodil
“The holy grail in this indication is a centrally acting, non-narcotic, not-sedating drug”
- Peter Dicpinigaits, MD, Professor, Albert Einstein School of Medicine; Editor-in-Chief, Lung
-
Ifenprodil has been shown to inhibit cough counts by ~40% (p<0.01) and almost doubled the time to cough (p<0.05).
-
These reductions were achieved at doses ~25% GluN2B receptor occupancy, enabling higher dosing to increase cough count reductions.
-
Ifenprodil has been shown to be safe at up to 8x-16x this dose level (NOAEL), enabling significant dose increases without causing toxicities.
Ifenprodil significantly reduces cough count and time to cough in vivo in preclinical models
-
-
Ifenprodil has been shown to inhibit geometric mean cough counts by ~40% (p<0.01) at week 12 in an open-label clinical trial.
-
Post-hoc responder analysis showed clear separation between ifenprodil and integrated placebo data from all prior IPF-refractory chronic cough trials.
-
The VAS score, a patient-reported measure of cough severity, was improved by 37.4% (23.6 mm, p = 0.001).
-
In the Global Rating of Change Scale, 58% of patients reported an improvement after 12 weeks; only 5% felt worse.
-
In the Leicester Cough Questionnaire, scores improved over 12 weeks (p = 0.017), and scores were improved in each domain.
Ifenprodil significantly reduces 24-hour cough counts and VAS scores in Phase 2a clinical trials in difficult-to-treat (IPF) patients with cough
-
-
Ifenprodil safety was described in a 15,018 subject post-marketing surveillance study at the same dose as was tested in our Phase 2a clinical trial (20 mg TID), and the drug had no safety concerns and was well tolerated.
-
We have generated data at double this dose (40 mg TID) in the clinic and the drug had no safety concerns and was well tolerated.
-
Importantly dose-limiting side effects associated with general NMDA channel blockers were absent in >99.5% of patients.
-
GluN2B receptor allosteric antagonist
Potential for a first- and best-in-class oral treatment for chronic cough
Ifenprodil is a small molecule allosteric antagonist of the NMDA receptor sub-type 2B, which reduces signaling through NMDA receptors that have GluN2B subunits present. Ifenprodil is not a general NMDA channel blocker, which is important as NMDA receptors control myriad functions in the brain.
